Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"ARNI's chairman is one of the best in the world in the urology field, and the company's consortium of investors has given us a lot of validation." (4/3/14) Arno Therapeutics Inc. - The Life Sciences Report Interview with Ran Nussbaum More >
Josh Levine has 25 years of senior-level experience analyzing trends in bio, energy and information technologies and investing in micro- and small-cap stocks. In 2002 he joined independent investment-research boutique ChangeWave Research, where he became editor of ChangeWave MicroCap Investor in 2004. This became Levine's MicroCap Investor in 2010. He is also senior analyst for ChangeWave Research, which manages a survey network comprised of 25,000 members to track the rate of change in corporate and consumer demand trends and provides the results through an institutional research subscription service. ChangeWave is a service of 451 Research, a leading global analyst and data company focused on the business of enterprise IT innovation.
Josh Levine Names Three Biotech Game-Changers (1/3/13) Micro-cap biotechs must have creative, adaptive management first and foremost, says editor Josh Levine of Josh Levine's MicroCap Investor. A second key characteristic is a technology platform that can ultimately generate a suite of products. In this interview with The Life Sciences Report, Levine shares both his investment philosophy and his best three biotech ideas, all of which he expects will return huge multiples to investors.
"The Phase 2 trial for VGX-3100 could be a major clinical validation of the power of INO's broadly applicable platform." (4/24/14) Inovio Pharmaceuticals Inc. - Charles Duncan, Piper Jaffray & Co. More >